BIOMERIEUX news, videos and press releases
For more news please use our advanced search feature.
BIOMERIEUX - More news...
BIOMERIEUX - More news...
- bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance
- bioMérieux Launches GENE-UP® TYPER,an Innovative Diagnostic Solution for Food Industries to Rapidly Analyze the Root Causeof Contamination of Listeria monocytogenes
- Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia
- Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
- bioMérieux Introduces GENE-UP® ENVIROPRO™
- French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
- Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
- bioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021
- bioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of May 20, 2021
- bioMérieux Announces the CE Marking of TB IGRA® Test on VIDAS®
- bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization
- bioMérieux – 2020 Financial Results
- bioMérieux Announces the CE Marking of NEPHROCHECK® Test on VIDAS®
- bioMérieux Announces the CE Marking of Its Molecular Biology ARGENE® Test for the Simultaneous Detection of SARS-CoV-2, Influenza Viruses A and B, and RSV and hMPV Viruses
- bioMérieux – Increased outlook for full-year 2020
- bioMérieux Announces the Expansion of the CE Marking of Its Molecular Biology ARGENE® SARS-CoV-2 Diagnostic Test to Include Saliva Specimens.
- bioMérieux – Third-Quarter 2020 Business Review
- bioMérieux – First-Half 2020 Results
- MERIEUX NutriSciences' EnviroMap Collaborates with BIOMERIEUX, Inc.
- bioMérieux: Launch of BIOFIRE® MYCOPLASMA Test for Mycoplasma Detection in Biopharmaceutical Products
- BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
- bioMérieux – Second-Quarter 2020 Business Performance Preannouncement
- bioMérieux: Description of the New Share Buyback Program Pursuant to Article 241-1 to Article 241-6 of the AMF General Regulations
- bioMérieux Issues a €200 Million Euro PP Bond
- bioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
- CE Marking of bioMérieux Serology Tests for SARS-CoV-2 on VIDAS®
- Information Concerning 2019 Dividend and the bioMérieux General Shareholders’ Meeting
- bioMérieux Serology Tests for SARS-CoV-2 on VIDAS® Undergo Validation Preceding Imminent Launch
- bioMérieux: BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 Obtains FDA Emergency Use Authorization
- bioMérieux – First-Quarter 2020 Business Review
